Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121529 | 0.88 | CHRM2 (0.70) | ALDH1A1GAACHRM2KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL9479560 | 0.86 | CHRM2 (0.68) | ALDH1A1GAACHRM2KDM4EPOLB | |
| Hydrochloric Acid SCHEMBL2147064 | 0.86 | CHRM2 (0.68) | ALDH1A1GAACHRM2KDM4EPOLB | |
| SCHEMBL10054983 | 0.83 | SLC2A4 (0.59) | ALDH1A1GAAKDM4EGLASMN1; SMN2 | |
| SCHEMBL22305119 | 0.82 | CHRM2 (0.63) | ALDH1A1GAACHRM2KDM4EPOLB | |
| SCHEMBL27924299 | 0.82 | CYP17A1 (0.67) | ALDH1A1GAAKDM4EHTTSMN1; SMN2 | |
| SCHEMBL8361612 | 0.82 | ALDH1A1 (0.64) | ALDH1A1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL5998644 | 0.81 | MAPT (0.65) | ALDH1A1GAAKDM4ENAMPT | |
| SCHEMBL10143918 | 0.81 | ALDH1A1 (0.67) | ALDH1A1HTTSMN1; SMN2PKMNAMPT | |
| SCHEMBL1043015 | 0.81 | ALDH1A1 (0.73) | ALDH1A1GAACHRM2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951033-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2018-04-24 | — | — | US | disclosed |
| US-9951033-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2018-04-24 | — | — | US | disclosed |
| US-9951033-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2018-04-24 | — | — | US | disclosed |
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2017-06-08 | — | — | US | disclosed |
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2017-06-08 | — | — | US | disclosed |
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2017-06-08 | — | — | US | disclosed |
| US-9556111-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2017-01-31 | — | — | US | disclosed |
| US-9556111-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2017-01-31 | — | — | US | disclosed |
| US-9556111-B2 | Tertiary amines for use in the treatment of cardiac disorders | UNIVERSITETET I OSLO (NO) | 2017-01-31 | — | — | US | disclosed |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2015-05-14 | — | — | US | disclosed |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2015-05-14 | — | — | US | disclosed |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2015-05-14 | — | — | US | disclosed |
| EP-2861568-A2 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | Universitetet I Oslo (NO) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013171332-A2 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | UNIVERSITETET I OSLO (NO) | 2013-11-21 | — | — | WO | disclosed |
| EP-1480941-B1 | UREA DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | AMBRILIA BIOPHARMA INC (CA) | 2011-01-26 | — | — | EP | disclosed |
| EP-1480941-A2 | UREA DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Procyon Biopharma Inc. (CA) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074467-A2 | UREA DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2003-09-12 | — | — | WO | disclosed |
| US-6528532-B1 | Benzenesulfonamide group | PHARMACOR INC. (CA) | 2003-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158657-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | ALDH1A1 1367/4885GAA 1759/4885CHRM2 1642/4885 |
| US-20150133510-A1 | TERTIARY AMINES FOR USE IN THE TREATMENT OF CARDIAC DISORDERS | TNNI3, TNNT2, MYLK2 | ALDH1A1 1191/4885GAA 1800/4885CHRM2 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.